haloperidol

Trade name: haldol

Small moleculeapproved

Approved

Apr 12, 1967

Haloperidol is a phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and Tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of Huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. Haloperidol also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ. Haloperidol is marketed under the trade name Haldol among others. — NCATS

Clinical trial activity

140 trials · 176 clinical orgs · 51 marketing orgs

Phase 1
11
Phase 2
46
Phase 3
36
Phase 4
52

Earliest trial started Apr 1, 1987 (NCT00946491)

Timeline

1960s

  1. Apr 12, 1967

    Johnson and Johnson — Earliest FDA Approval

  2. Apr 12, 1967

    Johnson and Johnson — NDA Organization

  3. Apr 12, 1967

    Johnson and Johnson — Marketing Organization

1970s

  1. May 18, 1971

    Johnson and Johnson — NDA Secondary Org

1980s

  1. Jun 10, 1986

    Mylan — Marketing Organization

  2. Nov 3, 1986

    Vintage — Marketing Organization

  3. Nov 3, 1986

    Strides Pharma Science — Marketing Organization

  4. Nov 3, 1986

    Puracap Pharmaceutical — Marketing Organization

  5. Nov 17, 1986

    Sandoz — Marketing Organization

  6. Nov 17, 1986

    Chartwell Pharmaceuticals — Marketing Organization

  7. Dec 4, 1986

    Duramed Research — Marketing Organization

  8. Jan 1, 1987

    Sandoz — Earliest Phase 1 Sponsor(trial)

  9. Jan 2, 1987

    ANDA Repository — Marketing Organization

  10. Jan 2, 1987

    Innogenix — Marketing Organization

  11. Jan 20, 1987

    Abraxis — Marketing Organization

  12. Feb 17, 1987

    Cycle Pharmaceuticals Ltd. — Marketing Organization

  13. Feb 17, 1987

    AiPing Pharm Inc — Marketing Organization

  14. Feb 17, 1987

    Sciegen Pharmaceticals — Marketing Organization

  15. Mar 6, 1987

    Watson Pharmaceuticals — Marketing Organization

  16. Aug 25, 1987

    Teva — Marketing Organization

  17. Apr 12, 1988

    Hikma — Marketing Organization

1990s

  1. Feb 25, 1993

    Marsam Pharmaceuticals — Marketing Organization

  2. Feb 26, 1993

    Pharmaceutical Associates — Marketing Organization

  3. Sep 28, 1993

    Lannett Company, Inc. — Marketing Organization

  4. Nov 2, 1995

    Actavis — Marketing Organization

  5. Dec 19, 1997

    Fresenius — Marketing Organization

  6. Jan 30, 1998

    West-Ward Pharmaceutical — Marketing Organization

  7. Jan 1, 1999

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Feb 9, 2000

    Hospira — Marketing Organization

  2. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

  3. Aug 25, 2004

    Gland Pharma Ltd — Marketing Organization

  4. Aug 25, 2004

    Baxalta — Marketing Organization

  5. Sep 29, 2004

    Fosun — Marketing Organization

  6. Jun 24, 2005

    Novartis — Marketing Organization

  7. Nov 29, 2007

    Zydus Discovery DMCC — Marketing Organization

2010s

  1. Sep 2, 2011

    Sagent Pharmaceuticals, Inc. — Marketing Organization

  2. Sep 6, 2017

    Akorn, Inc. — Marketing Organization

  3. Sep 6, 2017

    Epic Pharma Llc — Marketing Organization

  4. Jul 3, 2018

    Somerset Pharmaceuticals — Marketing Organization

2020s

  1. Jan 8, 2020

    Appco Pharma — Marketing Organization

  2. Jan 8, 2020

    Upsher-Smith Laboratories — Marketing Organization

  3. Jul 26, 2021

    Meitheal — Marketing Organization

  4. Jul 1, 2022

    AbbVie — Marketing Organization

  5. Nov 18, 2022

    MSN Laboratories — Marketing Organization

  6. May 23, 2023

    Mankind Pharma — Marketing Organization

  7. Jan 31, 2024

    Rubicon Research — Marketing Organization

  8. Apr 19, 2024

    Aurobindo Pharma — Marketing Organization

  9. May 13, 2025

    Caplin Point Laboratories — Marketing Organization

Indications

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewApr 12, 1967

Chemistry & pharmacology

Loading structure…

SMILES

O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
Mol. weight
375.87 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • 1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine
  • 1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine
  • 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
  • 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
  • 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
  • 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
  • 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
  • 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
  • 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
  • 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
  • aloperidin
  • dolpin
  • dozic
  • dozic
  • fortunan
  • fortunan
  • haldol
  • haldol
  • haldol
  • haldol
  • haldol dec
  • haldol dec
  • haldol decanoate
  • haldol solutab
  • haldol solutab
  • haloperidol
  • haloperidol
  • haloperidol
  • haloperidol
  • haloperidol
  • haloperidol
  • haloperidol
  • haloperidol
  • haloperidol
  • haloperidol
  • haloperidol
  • haloperidol decanoate
  • haloperidol decanoate
  • haloperidol decanoate
  • haloperidol decanoate
  • haloperidol decanoate
  • haloperidol decanoate
  • haloperidol intensol
  • haloperidol intensol
  • haloperidol lactate
  • haloperidol lactate
  • haloperidol lactate
  • haloperidol lactate
  • haloperidolum
  • haloperidolum
  • haloperin
  • kentace
  • keselen
  • lais
  • mcn-jr-1625
  • mcn-jr-1625
  • r-13672
  • r-13672
  • r-1625
  • r-1625
  • serenace
  • serenace
  • sigaperidol
  • γ-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone
  • γ-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07246187Phase 3Nov 6, 2025Mercy Bon Secours Saint Vincent Medical Center
NCT07109245Phase 4Sep 1, 2025The Physicians' Services Incorporated Foundation, University of Toronto
NCT06993194N/AJun 15, 2025Benha University
NCT07087925N/AJan 15, 2025Universitas Sumatera Utara
NCT06218524Phase 2Dec 1, 2024Southern Medical University
NCT06395428Phase 4Jul 9, 2024Western Michigan University
NCT06370442Phase 3Jun 1, 2024State University of New York, Syracuse
NCT06428084Phase 2Nov 1, 2023Padjadjaran University
NCT05690698Phase 3Apr 9, 2023Alexandria University, Suez Canal University
NCT05803642Phase 3Mar 28, 2023Qilu Pharmaceutical Co., Ltd.
NCT05431595Phase 2/Phase 3 (Phase 3)Dec 30, 2022State of Texas, University of Texas at Houston
NCT06168773Phase 2/Phase 3 (Phase 3)Nov 1, 2022Ain Shams University
NCT04833023Phase 3Nov 1, 2021Nanyang Technological University
NCT05106205Phase 1Oct 26, 2021Dong-A Pharmaceutical
NCT04750395Phase 2Sep 1, 2021HCA Hospice Care
NCT05065567Phase 2Aug 30, 2021The Spectrum Health Group
NCT04715230Phase 2Jun 30, 2021InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA)
NCT04764344Phase 4Apr 1, 2021Western Michigan University
NCT06014606N/AMar 1, 2021Maastricht University
NCT04529226Phase 2Sep 30, 2020Andalusian Health Service, Fundación Pública Andaluza
Showing 20 of 140 trials
Page 1 / 7

Organizations

Research & Development (176)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Johnson and JohnsonFor profit7531996
Eli LillyFor profit5421998
University of Texas at HoustonAcademic/Hospital5532012
National Cancer Institute (NCI)Government4032010
National Institute of Mental Health (NIMH)Government4021996
Canadian Institutes of Health Research (CIHR)Academic/Hospital3032005
Department of Veteran AffairsGovernment3321997
Friedrich Schiller UniversityAcademic/Hospital3112000
Janssen Pharmaceutica NVFor profit3021996
MerckFor profit3322005
National Institute on Aging (NIA)Government3131999
University of TorontoAcademic/Hospital3332006
Vanderbilt UniversityAcademic/Hospital3332004
Western Michigan UniversityAcademic/Hospital3312015
ZonMw: The Netherlands Organisation for Health Research and DevelopmentAcademic/Hospital3032010
Alexandria UniversityAcademic/Hospital2112003
American Cancer Society, Inc.Academic/Hospital2022010
Bristol-Myers SquibbFor profit2022004
Case Western Reserve UniversityAcademic/Hospital2222010
Columbia UniversityAcademic/Hospital2211999
176 organizations
Page 1 / 9

Marketing (64)

OrganizationOrg typeRelationshipDate
ANDA RepositoryFor profitMKTGJan 2, 1987
AbbVieFor profitMKTGJul 1, 2022
AbraxisFor profitMKTGJan 20, 1987
ActavisFor profitMKTGNov 2, 1995
ActavisFor profitSYNJul 1, 2022
AiPing Pharm IncFor profitMKTGFeb 17, 1987
Akorn, Inc.For profitMKTGSep 6, 2017
AlpharmaFor profitMKTG
Appco PharmaFor profitMKTGJan 8, 2020
Athenex, Inc.For profitMKTG
Aurobindo PharmaFor profitMKTGApr 19, 2024
BaxaltaFor profitMKTGAug 25, 2004
Boston Scientific CorporationFor profitMKTG
Caplin Point LaboratoriesFor profitMKTGMay 13, 2025
Chartwell PharmaceuticalsFor profitMKTGNov 17, 1986
Cycle Pharmaceuticals Ltd.For profitMKTGFeb 17, 1987
Cycle Pharmaceuticals Ltd.For profitSYNFeb 17, 1987
Duramed ResearchFor profitMKTGDec 4, 1986
Epic Pharma LlcFor profitMKTGSep 6, 2017
FosunFor profitMKTGSep 29, 2004
FreseniusFor profitMKTGDec 19, 1997
Gland Pharma LtdFor profitMKTGAug 25, 2004
Gland Pharma LtdFor profitSYNMay 12, 2017
HikmaFor profitMKTGApr 12, 1988
HikmaFor profitSYNApr 12, 1988
HospiraFor profitMKTGFeb 9, 2000
InnogenixFor profitMKTGJan 2, 1987
Johnson and JohnsonFor profitNDA2May 18, 1971
Johnson and JohnsonFor profitNDAApr 12, 1967
Johnson and JohnsonFor profitMKTGApr 12, 1967
Lannett Company, Inc.For profitMKTGSep 28, 1993
LederleFor profitMKTG
MSN LaboratoriesFor profitMKTGNov 18, 2022
Mankind PharmaFor profitMKTGMay 23, 2023
Marsam PharmaceuticalsFor profitMKTGFeb 25, 1993
MeithealFor profitMKTGJul 26, 2021
Morton Grove PharmaceuticalsFor profitMKTG
MylanFor profitMKTGJun 10, 1986
MylanFor profitSYNFeb 28, 2000
NovartisFor profitMKTGJun 24, 2005
Par PharmaceuticalsFor profitMKTG
Pharmaceutical AssociatesFor profitMKTGFeb 26, 1993
Puracap PharmaceuticalFor profitMKTGNov 3, 1986
Quantum PharmaceuticalFor profitMKTG
Rubicon ResearchFor profitMKTGJan 31, 2024
Rubicon ResearchFor profitSYNJan 31, 2024
SOLOPAKFor profitMKTG
Sagent Pharmaceuticals, Inc.For profitMKTGSep 2, 2011
Sagent Pharmaceuticals, Inc.For profitNDA2
SandozFor profitMKTGNov 17, 1986
SandozFor profitSYNJun 24, 2005
Sciegen PharmaceticalsFor profitMKTGFeb 17, 1987
Smith & NephewFor profitMKTG
Somerset PharmaceuticalsFor profitMKTGJul 3, 2018
Strides Pharma ScienceFor profitMKTGNov 3, 1986
TevaFor profitMKTGAug 25, 1987
TevaFor profitSYNDec 1, 1988
TevaFor profitSYNMay 11, 1999
Upsher-Smith LaboratoriesFor profitMKTGJan 8, 2020
VintageFor profitMKTGNov 3, 1986
Watson PharmaceuticalsFor profitMKTGMar 6, 1987
West-Ward PharmaceuticalFor profitMKTGJan 30, 1998
Zydus Discovery DMCCFor profitMKTGNov 29, 2007
Zydus Discovery DMCCFor profitSYNOct 22, 2019